| abstract |
The invention provides a bridged ring compound as a hepatitis C inhibitor, its pharmaceutical composition and application. The compound is a compound represented by formula (I) or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, Pharmaceutically acceptable salts or prodrugs. In addition, the present invention also provides a pharmaceutical composition comprising the compound, the use of the compound and the pharmaceutical composition for at least one of inhibiting the HCV replication process and inhibiting the function of the HCV viral protein, and the compound and the The pharmaceutical composition is used for preventing, treating, treating or alleviating HCV infection or hepatitis C disease in a patient. |